Detection of metabolic dysfunctions using fluorescence emission from serum

• US 6,813,009 B2
• Filed: 09/18/2001
• Issued: 11/02/2004
• Est. Priority Date: 09/18/2001
• Status: Expired due to Fees

• Current Assignee: Riordan Clinic Incorporated
• Original Assignee: The Center For The Improvement Of Human Functioning, International, Inc.
• Inventors: Riordan, Hugh D., Mikarova, Nina, Rillema, Paul
• Primary Examiner(s): Font, Frank G.
• Assistant Examiner(s): Brown, Khaled
• Application Number:
  US09/956,504
• Publication Number:
  US 20030137649A1
• Time in Patent Office: 1,141 Days
• Field of Search: 356/39, 356/300, 356/303, 356/337, 356/451, 356/456, 204/450, 204/451
• US Class Current: 356/39
• CPC Class Codes: G01N 2021/6423 Spectral mapping, video display
• CPC Class Codes: G01N 21/6486 Measuring fluorescence of biological material, e.g. DNA, RNA, cells G01N21/6428 takes precedence

Abstract

Serum emission can be used as the first test to detect metabolic disorders in mammals. When changes in emission of the serum from patients with different pathological conditions were characterized, a difference was seen for patients with diseases such as cancer, thyroid disorder, arthritis, diabetes, coronary artery disease (CAD), hypertension, CFS (chronic fatigue syndrome), and fibromyalgia. The level of emission was enhanced or diminished and correlated with the level of energy metabolism and the level of metabolic rate. The method can also be used for risk assessment, to identify whether a treatment is working or to follow the course of a treatment, and to identify changes in energy levels due to stress, etc.

Claims

1. A method for the diagnosis of a disease of metabolic dysfunction, comprising:

obtaining a sample of serum from a patient;

irradiating the sample with a plurality of irradiation wavelengths from about 300 to about 340 nm simultaneously;

measuring the serum emission at one or more wavelengths from about 300 to about 600 nm; and

diagnosing the presence of a metabolic dysfunction by an increased or decreased emission in comparison to an average emission at said wavelength of serum of a plurality of normal healthy volunteers.

2. The method of claim 1 wherein said emission wavelength is from about 330 to about 550.

3. The method of claim 1 wherein said emission wavelength is from about 370 to about 550.

4. The method of claim 1 wherein said emission wavelength is from about 425 to about 500.

5. The method of claim 1 wherein said emission wavelength is from about 470 to about 500.

6. The method of claim 1 wherein said emission wavelength is from about 460 to about 490.

7. The method of claim 1 wherein said plurality of irradiation wavelengths is selected from the group consisting of:

315, 325 and 340.

8. The method of claim 1 wherein said metabolic dysfunction is cancer and the serum emission is reduced.

9. The method of claim 8 wherein a patient with cancer has more than a 5% decrease in the level of serum emission.

10. The method of claim 8 wherein a patient with cancer has more than a 10% decrease in the level of serum emission.

11. The method of claim 8 wherein a patient with cancer has more than a 20% decrease in the level of serum emission.

12. The method of claim 8 wherein a patient with cancer has a decrease in the serum emission from about 5% to about 60%.

13. The method of claim 8 wherein a patient with cancer has a decrease in the serum emission from about 10% to about 50%.

14. The method of claim 8 wherein said cancer is selected from the group consisting of:

breast cancer, lung cancer, colon cancer, prostate cancer and leukemia.

15. The method of claim 1 wherein said metabolic dysfunction is hypothyroidism and the serum emission is reduced.

16. The method of claim 1 wherein said metabolic dysfunction is hyperthyroidism and the serum emission is increased.

17. The method of claim 1 wherein said metabolic dysfunction is diabetes and the serum emission is reduced.

18. The method of claim 1 wherein said metabolic dysfunction is fatigue and the serum emission is reduced.

19. The method of claim 1 wherein said metabolic dysfunction is coronary artery disease (CAD) and the serum emission is reduced.

20. The method of claim 1 wherein said sample is irradiated at both 325 nm and 340 nm.

21. The method of claim 1, wherein said sample is irradiated at the wavelength which allows the best resolution for NAD(P)H.

22. The method of claim 1 wherein said patient has fasted for more than about 8 hours before the sample is taken.

23. The method of claim 1, wherein said patient has fasted for about 2 to about 24 hours before the sample is taken.

24. The method of claim 23, wherein said patient has fasted for about 8 to about 12 hours before the sample is taken.

25. The method of claim 24, wherein said patient has fasted for about 10 to about 12 hours before the sample is taken.

26. A method for analysis of the effectiveness of a treatment, comprising:

obtaining a first sample of serum from a patient before the treatment;

irradiating the first sample at more than one irradiation wavelength from about 300 to about 340 nm simultaneously;

measuring the serum emission at at least one emission wavelength from about 300 to about 600 nm;

obtaining a second sample of serum from a patient after the treatment, wherein said patient has fasted for at least about 8 hours prior to obtaining the first sample;

irradiating the second sample at more than one irradiation wavelength from about 300 to about 340 nm simultaneously;

measuring the serum emission at at least one emission wavelength from about 300 to about 600 nm; and

diagnosing the effectiveness of the treatment by an increased or decreased emission in the second sample relative to the first sample.

27. The method of claim 26, wherein the treatment is a treatment for cancer and the treatment is diagnosed as being effective by an increased emission.

28. The method of claim 26, wherein said patient has fasted for at least about 8 hours prior to obtaining the first and subsequent samples.

29. The method of claim 26, wherein said patient has fasted for at least about 2 hours prior to about 24 hours before obtaining the first and subsequent samples.

30. The method of claim 26, wherein said patient has fasted for at least about 6 hours prior to about 12 hours before obtaining the first and subsequent samples.

31. The method of claim 26 wherein said emission is measured at more than one emission wavelength simultaneously.